ATE273285T1 - Neue guanidin-derivate als zelladhäsion- inhibitoren - Google Patents

Neue guanidin-derivate als zelladhäsion- inhibitoren

Info

Publication number
ATE273285T1
ATE273285T1 AT00905022T AT00905022T ATE273285T1 AT E273285 T1 ATE273285 T1 AT E273285T1 AT 00905022 T AT00905022 T AT 00905022T AT 00905022 T AT00905022 T AT 00905022T AT E273285 T1 ATE273285 T1 AT E273285T1
Authority
AT
Austria
Prior art keywords
cell adhesion
formula
compounds
guanidine derivatives
adhesion inhibitors
Prior art date
Application number
AT00905022T
Other languages
English (en)
Inventor
Anuschirwan Peyman
Jochen Knolle
Karl-Heinz Scheunemann
David William Will
Denis Carniato
Jean-Francois Gourvest
Thomas Gadek
Sarah Catherine Bodary
Original Assignee
Aventis Pharma Gmbh
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh, Genentech Inc filed Critical Aventis Pharma Gmbh
Application granted granted Critical
Publication of ATE273285T1 publication Critical patent/ATE273285T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
    • C07D239/12—Nitrogen atoms not forming part of a nitro radical
    • C07D239/16—Nitrogen atoms not forming part of a nitro radical acylated on said nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT00905022T 1999-02-13 2000-02-04 Neue guanidin-derivate als zelladhäsion- inhibitoren ATE273285T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99102916A EP1028114A1 (de) 1999-02-13 1999-02-13 Neue Guanidin-Derivate als Inhibitoren der Zelladhäsion
PCT/EP2000/000895 WO2000047564A1 (en) 1999-02-13 2000-02-04 Novel guanidine derivatives as inhibitors of cell adhesion

Publications (1)

Publication Number Publication Date
ATE273285T1 true ATE273285T1 (de) 2004-08-15

Family

ID=8237555

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00905022T ATE273285T1 (de) 1999-02-13 2000-02-04 Neue guanidin-derivate als zelladhäsion- inhibitoren

Country Status (11)

Country Link
US (1) US6340679B1 (de)
EP (2) EP1028114A1 (de)
JP (1) JP4642242B2 (de)
AT (1) ATE273285T1 (de)
AU (1) AU768206B2 (de)
CA (1) CA2371789C (de)
DE (1) DE60012890T2 (de)
ES (1) ES2225086T3 (de)
IL (1) IL144725A0 (de)
MX (1) MXPA01008072A (de)
WO (1) WO2000047564A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19629816A1 (de) * 1996-07-24 1998-01-29 Hoechst Ag Neue Cycloalkyl-Derivate als Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten
US6972296B2 (en) 1999-05-07 2005-12-06 Encysive Pharmaceuticals Inc. Carboxylic acid derivatives that inhibit the binding of integrins to their receptors
DK1265606T3 (da) 1999-08-13 2007-02-12 Biogen Idec Inc Celleadhæsionsinhibitorer
JP4750360B2 (ja) 2001-10-22 2011-08-17 ザ スクリプス リサーチ インスティチュート 抗体ターゲッティング化合物
EP1682537B1 (de) 2003-11-05 2012-03-28 SARcode Bioscience Inc. Modulatoren der zellulären adhäsion
US7196112B2 (en) 2004-07-16 2007-03-27 Biogen Idec Ma Inc. Cell adhesion inhibitors
DK1881823T3 (en) * 2005-05-17 2015-03-02 Sarcode Bioscience Inc COMPOSITION AND PROCEDURES FOR TREATMENT OF EYE DISORDERS
EP1945262A2 (de) * 2005-10-20 2008-07-23 The Scripps Research Institute Fc-etikettierung für immunostaining und immunotargeting
AU2008317473B2 (en) 2007-10-19 2014-07-17 Bausch + Lomb Ireland Limited Compositions and methods for treatment of diabetic retinopathy
CN102056485A (zh) * 2008-04-15 2011-05-11 萨可德公司 用于局部治疗免疫相关疾病的局部lfa-1拮抗剂
WO2009139817A2 (en) 2008-04-15 2009-11-19 Sarcode Corporation Crystalline pharmaceutical and methods of preparation and use thereof
JP2011518155A (ja) * 2008-04-15 2011-06-23 サーコード コーポレイション 免疫関連障害の局所治療に使用するためのエアゾール化ｌｆａ−１アンタゴニスト
CN102065893A (zh) * 2008-04-15 2011-05-18 萨可德公司 Lfa-1拮抗剂向胃肠系统的递送
US8518927B2 (en) 2009-02-10 2013-08-27 The Scripps Research Institute Chemically programmed vaccination
WO2011050175A1 (en) 2009-10-21 2011-04-28 Sarcode Corporation Crystalline pharmaceutical and methods of preparation and use thereof
WO2014018748A1 (en) 2012-07-25 2014-01-30 Sarcode Bioscience Inc. Lfa-1 inhibitor and polymorph thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5204350A (en) 1991-08-09 1993-04-20 Merck & Co., Inc. Method of inhibiting osteoclast-mediated bone resorption by administration of n-heterocyclicalkyl-substituted phenyl derivatives
US5217994A (en) 1991-08-09 1993-06-08 Merck & Co., Inc. Method of inhibiting osteoclast-mediated bone resorption by administration of aminoalkyl-substituted phenyl derivatives
US5250679A (en) 1991-10-18 1993-10-05 Genentech, Inc. Nonpeptidyl platelet aggregation inhibitors having specificity for the GPIIb III.sub. receptor
JP3322878B2 (ja) 1992-10-14 2002-09-09 メルク エンド カンパニー インコーポレーテッド フィブリノーゲンレセプターアンタゴニスト
CA2150550A1 (en) 1992-12-01 1994-06-09 Melissa S. Egbertson Fibrinogen receptor antagonists
ES2186720T3 (es) 1994-05-27 2003-05-16 Merck & Co Inc Composiciones para inhibir la reabsorcion osea mediada por osteoclastos.
JPH10504807A (ja) 1994-06-29 1998-05-12 スミスクライン・ビーチャム・コーポレイション ビトロネクチン受容体拮抗剤
BR9508178A (pt) 1994-06-29 1997-11-18 Smithkline Beecham Corp Antagonistas de receptor de vitronectina
EP0844874B1 (de) 1995-08-14 2005-11-09 The Scripps Research Institute VERFAHREN UND MITTEL ZUR HEMMUNG DER DURCH ALPHA v BETA 5 VERMITTELTEN ANGIOGENESE
DE19548709A1 (de) * 1995-12-23 1997-07-03 Merck Patent Gmbh Tyrosinderivate
CZ424998A3 (cs) * 1996-06-28 1999-03-17 Merck Patent Gmbh Deriváty fenylaminu jakožto integrinové inhibitory
DE19629816A1 (de) * 1996-07-24 1998-01-29 Hoechst Ag Neue Cycloalkyl-Derivate als Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten
EP0933367A1 (de) * 1997-12-19 1999-08-04 Hoechst Marion Roussel Deutschland GmbH Acylguanidin Derivate als Inhibitoren von Knochenaufsauge und als Vitronectin Rezeptor Antagonisten
BR9907735A (pt) 1998-01-23 2000-10-17 Aventis Pharma Gmbh Derivados de sulfonamida como inibidores da reabsorção óssea e como inibidores da aderência celular

Also Published As

Publication number Publication date
AU768206B2 (en) 2003-12-04
JP2002536438A (ja) 2002-10-29
AU2669900A (en) 2000-08-29
EP1155003A1 (de) 2001-11-21
US6340679B1 (en) 2002-01-22
CA2371789C (en) 2009-04-14
EP1028114A1 (de) 2000-08-16
DE60012890D1 (de) 2004-09-16
ES2225086T3 (es) 2005-03-16
EP1155003B1 (de) 2004-08-11
CA2371789A1 (en) 2000-08-17
WO2000047564A1 (en) 2000-08-17
JP4642242B2 (ja) 2011-03-02
DE60012890T2 (de) 2005-08-25
MXPA01008072A (es) 2002-07-30
IL144725A0 (en) 2002-06-30

Similar Documents

Publication Publication Date Title
MY122269A (en) Novel acylguanidine derivatives as inhibitors of bone resorption and as vitronection receptor antagonists
ATE273285T1 (de) Neue guanidin-derivate als zelladhäsion- inhibitoren
BG104630A (en) Novel sulfonamide derivatives as inhibitors of bone resorption and as inhibitors of cell adhesion
CA2225366A1 (en) Substituted purine derivatives, processes for their preparation, their use, and compositions comprising them
BR0109235A (pt) Derivados do ácido carboxìlico como antagonistas ip
BRPI0203172B8 (pt) composição farmacêutica para acondroplasia
DK0894084T3 (da) Kanelsyrederivater og deres anvendelse som integrinantagonister
CY1106522T1 (el) Ετepοκυκλικη ενωση και αντικαρκινικο μεσο που πepιεχει την ιδια ως δραστικο συστατικο
BR0212069A (pt) Agentes antidiabéticos orais
MY133246A (en) Naphthyridine derivatives, processes for their preparation, their use and pharmaceutical compositions comprising them
EA200200121A1 (ru) Замещенные производные пурина в качестве ингибиторов клеточной адгезии
DK1165544T3 (da) Substituerede 1,4-dihydroindeno[1,2-c]pyrazoler som inhibitorer af tyrosinkinase
AU2001277752A1 (en) Calcium receptor antagonists
BR9917315A (pt) Composições medicinais para liberação imediata para uso oral
ATE360018T1 (de) Thienylalaninderivate als inhibitoren der zelladhäsion
ATE432934T1 (de) Neue guanidino derivate als zelladhäsionhemmer
AR030874A1 (es) Ester isopropilico de acido (2s)-2-(adamantan-1-ilmetoxicarbonilamino)-3-(4-(2-(1,4,5,6-tetrahidropirimidin-2-ilcarbamoil)etil)benzoilamino)propionico, su preparacion y su uso
TH65078A (th) อนุพันธ์ไพร์โรลิดีนออกซาไดอะโซล-และไทอะไดอะโซล
ATE524442T1 (de) Antiproliferative wirkstoffe
TW200607498A (en) Agents for prevention or treatment of diseases associated with endothelial hyperproliferation
TH64558A (de)

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties